CA1196863A - Slow release injectable insulin composition - Google Patents
Slow release injectable insulin compositionInfo
- Publication number
- CA1196863A CA1196863A CA000429960A CA429960A CA1196863A CA 1196863 A CA1196863 A CA 1196863A CA 000429960 A CA000429960 A CA 000429960A CA 429960 A CA429960 A CA 429960A CA 1196863 A CA1196863 A CA 1196863A
- Authority
- CA
- Canada
- Prior art keywords
- insulin
- albumin
- composition
- microbeads
- glutaraldehyde
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
Abstract
ABSTRACT OF THE DISCLOSURE
A slow release injectable insulin composition is provided which is able to control blood sugar levels over extended periods of time. The albumin is partially cross-linked using a concentration of glutaraldehyde which is less than 3.75% v/w of the albumin to form a matrix enclosing the insulin. The composition conveniently is provided in the form of microbeads.
A slow release injectable insulin composition is provided which is able to control blood sugar levels over extended periods of time. The albumin is partially cross-linked using a concentration of glutaraldehyde which is less than 3.75% v/w of the albumin to form a matrix enclosing the insulin. The composition conveniently is provided in the form of microbeads.
Description
SLOW REL~ASE INJECTABLE INSULIM COMPOSITIOM
The present invention relates to long-lastiny injectable insulin composi.-tions.
Nor~oglycemia in diabetic patients is controlled by the injection of insulin into the body of the patient. Insulin injections several times a day are required, although more recently long lasting ultralente and protamine æinc insulin has decreased the frequency of injection for some diabetics to once every day.
There is a need for a system which would permit the administration of one large dose of insulin at widely-spaced intervals of weeks or even months.
Such a large dose would need to be associated with some means of permitting the administered insulin to be released into the blood stream over a long period of time, so as to be effective over that period.
It has previously been suggested in European Patent Publication No. 0,054,396, published June 23, 1982, to provide implants, microbeads and microcapsules suitable for injection into an animal body comprising cross-linked but physically-native albumin and a non-albumin substance, such as, a steroid or an enzyme.
Upon injection or implantation into an animal bodyj the non-albumin substance contained therein is released slowly as the cross-linked albumin is slowly dissolved by biodegradation Although this prior art publication does not mention insulin as a potential non-albumin substance, superficially this prior art approach would seem promising for the production of long term insulin release. When the cross-linking procedure which is described in the prior art publication using glutaraldehyde, is attempted to be used in conjunction with insulin as the non-albumin substance, the resulting product is ineffective in decreasing blood sugar levels upon injection or implantation in a body.
It has now surprisingly been found that there can be produced a biodegradable composition comprising '~
.~
68~;~
insulin which is able -to achi.eve long lasting release of insulin into -the blood stream suf~icient to control blood sugar levels upon injection or implantation.
In accordance with one aspect of the present invention, there is provided a biodegradable insulin-containing composition suitable for administration to a living body for the control of blood sugar levels therein, comprising a matrix of partially cross-linked physically-native albumin and insulin wherein the extent of the partial cross-linking is such as to permit insulin to be released from the matrix by diffusion and/or erosion when positioned in the body.
In order to provide the desired degree of partial cross~linking, albumin is partially cross-linked only using less than a critical upper limit of proportion of glutaraldehyde cross-linking agent, namely 3.75% v/w of glutaraldehyde to albumin.
Accordingly, in another aspect of the invention there is provided a method of fo~mation of an insulin-containing biodegradable composition, which comprises forming an aqueous suspension oE native albumin, insulin crystals and glutaraldehyde in a concentration of less than 3.75% v/w of the albumin;
adding the aqueous suspension to an oil phase under shear to form a water-in-oil emulsion and to cross-link the albumin to form microbeads of a matrix of partially cross-linked albumin and insulin which permit insulin to be released therefrom by diffusion and/or erosion when positioned in the body; and recovering the microbeads from the oil phase.
By only partially cross-linking the albumin, the insulin which entrapped within the resulting matrix is able to be released over a period of several weeks to several months and achieve blood sugar level control over that period.
In the present invention, therefore, a biodegradable matrix of albumln and insulin is providedO Albumin from any convenient source may be ~ .:
6i5 ~i3 used, lncludi.ng human ~lood, and is partially cross-linked under relatively mlld conditions to form the matrix of albumin in a substan-tially native form.
As noted above, injectable insulin-protein microbeads according to the invention may be prepared by adding an aqueous suspension, containing protein albumin, insulin crystals and glutaraldehyde cross-linking agent, to a rapidly stirred oil phase to form a water-in-oil emulsion of small water droplets containing protein, insulin and glutaraldehyde in a continuous oil phase. The stirring is stopped once the cross-linking reaction is complete and the resulting microbeads are recovered from the oil phase.
By providing the matrix of cross-linked albumin and insulin in microbead form, administration to the human body is facilitated, since the microbeads are of a size suitable for injection. The matrix however, may be provided in other implantable or injectable forms, such as, pellets or thin sheets.
The most critical parameter of the cross-linking process is the concentration of glutaraldehyde cross-linking agent for the albumin which is used. At a concentration of glutaraldehyde of 3.75% v/w or above, the product which is produced is ineffective in releasing insulin sufficiently to decrease blood sugar levels, whereas at a concentration of glutaraldehyde of less than 3.75% v/w, there is produced a matrix which is effective in permitting sufficient insulin release to achieve a decrease in blood sugar levels. It is noted that the prior art process of European Patent Publication No. 0,054,396 suggests utilization of 5.0% v/w of glutaraldehyde for cross-linking. As indicated above, at such glutaraldehyde concentrations when insulin is used, the product is ineffective in decreasing blood sugar levels.
In the process of the invention, the temperature at which the albumin solution is maintained during and after dispersion of the insulin therein i3 general]y does not exceed 37C and desirably does not exceed 20C, and is preferably in the range of 0 -to lO''C, most preferably 0 -to 5C. The pH of the albumin solution is preferably maintained in the range of about S 5.5 to about 8.5 and most preferably about 7.
To ensure rapid formation of the implants, microcapsules or microbeads, the albumin solution should be relatively concentrated, being at least 10%
w/v. However, it is preferred that the concentration of the albumin solution should not exceed about 50% ~/v and preferably not exceed 30% w/v.
The process of the invention may be utilized to entrap any desired proportion of insulin, up to about 50 wt% of the matrix. Usually, the proportion of insulin in the product is about 5 to about 40% w/w of the microbeads.
Insulin release from the matrix of partially cross-linked albumin and insulin may be usefully controlled by diffusion or erosion. By increasing the cross-linking density as a result of an increase in the glutaraldehyde concentration, the erosion of the matrix is slower than insulin diffusion, and the rate of insulin release, therefore, declines continuously. If insulin is well immobilized in the solid matrix so that diffusional release is minimal and erosion is relatively fast, the rate of insulin release may be controlled by erosion. This result may be achieved, for example, by utilizing very little cross-linking agent and pre-binding the insulin to another molecule, such as, a stearylated amino acid~
In addition to the product of the invention being biocompatible, inexpensible and versatile, the matrix material has a long shelf life. Insulin-albumin microbeads, for example, may be stored at 4C for many months prior to implantation without loss of effectiveness.
The invention is illustrated further by the following Examples:
. ' . ,i i3 Exarnple 1 This Example illustrates the preparation of insulln-containing microbeads.
40 mg of beef insulin crystals (23.3 U/mg) were suspended in 0~8 ml of sodium phosphate buffer (1 mM, pH 7.5) containing sodium dodecyl sulfate (1%).
160 mg of bovine serum albumin (BSA~ of molecular weight of 67,000 Daltons was dissolved in the suspension which was maintained at 4C. Cross-linking was initiated by the addition of 0.2 ml of glutaraldehyde solution (2.5~ v/v) to provide a final glutaraldehyde concentration of 3.12% v/w of the albumin.
- After rapid mixing, the suspension was pipetted into 50 ml of a stirred solution of a corn oil and petroleum ether (1:4 by volume). The water-in-oil emulsion which formed was stirred at room temperature for fifteen minutes. The oil phase was decanted, the microbeads were washed three -times with petroleum ether and then dried overnight by weight of in a fume hood.
The dry microbeads contained 20% insulin and were stored dry at ~C.
Example 2 This Example illustrates the effect on blood sugar levels obtained by administration of the insulin microbeads formed by the procedure of Example 1.
(a) Implantation of Insulin Microbeads:
150 mg dry microbeads produced by the procedure of Example 1 were implanted subcutaneously in the flanks of chemically-induced diabetic rats, by means of a small incision in the skin. The blood insulin levels in the treated rats were monitored over a 21-day period and compared to those for untreated rats. The results are reproduced in the following Table I:
Table I
~ . ...
Days 0 3 7 10 14 17 21 Blood insulin 5 levels (~U/ml) ~treated diabetic rats (N=8) 14 51 62 75 63 38 21 -control diabetic rats (N=4) 11 6 9 10 6 3 9 10 As may be seen ~rom the results of Table I, after implantation of the microbeads, the insulin levels gradually increased to reach a maximum at 10 days post-implantation, after which there was a gradual decrease. The blood insulin level remained -elevated for up to 3 weeks after implantatlon, demonstrating the longevity of effectiveness of the product of the invention. There was no significant increase in blood-insulin levels in the con-trol animals.
The blood`glucose levels of the same diabetic rats with insulin microbead implants were monitored over the same 21-day period and again compared with -the non-treated rats. The results are reproduced in the following Table II:
Table II
Days 0 3 7 10 14 17 21 Blood sugar levels (mg%) -treated diabetic 30 rats (N=8) 370 95 91 84 105 305 380 -control diabe-tic rats (N=4) 380 390 387 392 400 404 406 As may be seen from the results of the above Table II, after implantation of the microbeads, the blood glucose levels fell from 370 mg per cent to 95 mg per cent and remained stable for 14 days. By day 21, all the animals were hyperglycemic. The control animals did not display any decrease in their high blood glucose levels.
i3 Body weight changes were also rnonitored during the test period and in all cases, the treated diabetic rats yained in weight while the control rats did not, as may be seen from the following Table III:
Table III
Days 0 3 7 10 14 Body weight (g) ~ -treated diabetic rats lu (N=8) 185 200 210 220 230 -control diabetic rats (N=4) 190 185 180 180 175 (b) Injection of Insulln Microbeads 40 mg of insulin microbeads were mixed with 2 ml of a glycerol/saline solution containing 75% of glycerol by weight and injected subcutaneously into diabetic rats with a 16~gauge needle. The results obtained were similar to those observed for implanted microbeads.
Example 3 This Example illustrates the effect of the concentration of glutaraldehyde used to cross-link albumin.
The procedure of Example 1 was repeated using varying concentrations of glutaraldehyde from 0.2 to 1.0~ v/v and, for the microbeads produced in each experiment, the effective period over which blood glucose levels were decreased was determined. In each case, 150 mg of insulin microbeads were subcutaneously implanted and the results reproduced in the following Table IV are a mean of three tests.
Table IV
~ Glut- 1.25 1.87 2.5 3.12 3.75 4.37 5.0 5.62 6.25 araldehyde v/w albumin No. of 11 13 13 14 0 0 0 0 0 days Blood Glucose levels lowered i3 As may be seen frorn the results of Table IV, at glu-taraldehyde concen-trations of 3.75~ v/w and above, the insulin microbeads are ineffective in producing a decrease in blood sugar levels, whereas sustained blood sugar control is achieved when the cross-linking is efCected usiny lower concentrations.
In summary of this disclosure, the present invention provides a novel long-acting implantable insulin composition which does not suffer from the drawbacks of prior art procedures. Modifications are possible within the scope of the invention.
The present invention relates to long-lastiny injectable insulin composi.-tions.
Nor~oglycemia in diabetic patients is controlled by the injection of insulin into the body of the patient. Insulin injections several times a day are required, although more recently long lasting ultralente and protamine æinc insulin has decreased the frequency of injection for some diabetics to once every day.
There is a need for a system which would permit the administration of one large dose of insulin at widely-spaced intervals of weeks or even months.
Such a large dose would need to be associated with some means of permitting the administered insulin to be released into the blood stream over a long period of time, so as to be effective over that period.
It has previously been suggested in European Patent Publication No. 0,054,396, published June 23, 1982, to provide implants, microbeads and microcapsules suitable for injection into an animal body comprising cross-linked but physically-native albumin and a non-albumin substance, such as, a steroid or an enzyme.
Upon injection or implantation into an animal bodyj the non-albumin substance contained therein is released slowly as the cross-linked albumin is slowly dissolved by biodegradation Although this prior art publication does not mention insulin as a potential non-albumin substance, superficially this prior art approach would seem promising for the production of long term insulin release. When the cross-linking procedure which is described in the prior art publication using glutaraldehyde, is attempted to be used in conjunction with insulin as the non-albumin substance, the resulting product is ineffective in decreasing blood sugar levels upon injection or implantation in a body.
It has now surprisingly been found that there can be produced a biodegradable composition comprising '~
.~
68~;~
insulin which is able -to achi.eve long lasting release of insulin into -the blood stream suf~icient to control blood sugar levels upon injection or implantation.
In accordance with one aspect of the present invention, there is provided a biodegradable insulin-containing composition suitable for administration to a living body for the control of blood sugar levels therein, comprising a matrix of partially cross-linked physically-native albumin and insulin wherein the extent of the partial cross-linking is such as to permit insulin to be released from the matrix by diffusion and/or erosion when positioned in the body.
In order to provide the desired degree of partial cross~linking, albumin is partially cross-linked only using less than a critical upper limit of proportion of glutaraldehyde cross-linking agent, namely 3.75% v/w of glutaraldehyde to albumin.
Accordingly, in another aspect of the invention there is provided a method of fo~mation of an insulin-containing biodegradable composition, which comprises forming an aqueous suspension oE native albumin, insulin crystals and glutaraldehyde in a concentration of less than 3.75% v/w of the albumin;
adding the aqueous suspension to an oil phase under shear to form a water-in-oil emulsion and to cross-link the albumin to form microbeads of a matrix of partially cross-linked albumin and insulin which permit insulin to be released therefrom by diffusion and/or erosion when positioned in the body; and recovering the microbeads from the oil phase.
By only partially cross-linking the albumin, the insulin which entrapped within the resulting matrix is able to be released over a period of several weeks to several months and achieve blood sugar level control over that period.
In the present invention, therefore, a biodegradable matrix of albumln and insulin is providedO Albumin from any convenient source may be ~ .:
6i5 ~i3 used, lncludi.ng human ~lood, and is partially cross-linked under relatively mlld conditions to form the matrix of albumin in a substan-tially native form.
As noted above, injectable insulin-protein microbeads according to the invention may be prepared by adding an aqueous suspension, containing protein albumin, insulin crystals and glutaraldehyde cross-linking agent, to a rapidly stirred oil phase to form a water-in-oil emulsion of small water droplets containing protein, insulin and glutaraldehyde in a continuous oil phase. The stirring is stopped once the cross-linking reaction is complete and the resulting microbeads are recovered from the oil phase.
By providing the matrix of cross-linked albumin and insulin in microbead form, administration to the human body is facilitated, since the microbeads are of a size suitable for injection. The matrix however, may be provided in other implantable or injectable forms, such as, pellets or thin sheets.
The most critical parameter of the cross-linking process is the concentration of glutaraldehyde cross-linking agent for the albumin which is used. At a concentration of glutaraldehyde of 3.75% v/w or above, the product which is produced is ineffective in releasing insulin sufficiently to decrease blood sugar levels, whereas at a concentration of glutaraldehyde of less than 3.75% v/w, there is produced a matrix which is effective in permitting sufficient insulin release to achieve a decrease in blood sugar levels. It is noted that the prior art process of European Patent Publication No. 0,054,396 suggests utilization of 5.0% v/w of glutaraldehyde for cross-linking. As indicated above, at such glutaraldehyde concentrations when insulin is used, the product is ineffective in decreasing blood sugar levels.
In the process of the invention, the temperature at which the albumin solution is maintained during and after dispersion of the insulin therein i3 general]y does not exceed 37C and desirably does not exceed 20C, and is preferably in the range of 0 -to lO''C, most preferably 0 -to 5C. The pH of the albumin solution is preferably maintained in the range of about S 5.5 to about 8.5 and most preferably about 7.
To ensure rapid formation of the implants, microcapsules or microbeads, the albumin solution should be relatively concentrated, being at least 10%
w/v. However, it is preferred that the concentration of the albumin solution should not exceed about 50% ~/v and preferably not exceed 30% w/v.
The process of the invention may be utilized to entrap any desired proportion of insulin, up to about 50 wt% of the matrix. Usually, the proportion of insulin in the product is about 5 to about 40% w/w of the microbeads.
Insulin release from the matrix of partially cross-linked albumin and insulin may be usefully controlled by diffusion or erosion. By increasing the cross-linking density as a result of an increase in the glutaraldehyde concentration, the erosion of the matrix is slower than insulin diffusion, and the rate of insulin release, therefore, declines continuously. If insulin is well immobilized in the solid matrix so that diffusional release is minimal and erosion is relatively fast, the rate of insulin release may be controlled by erosion. This result may be achieved, for example, by utilizing very little cross-linking agent and pre-binding the insulin to another molecule, such as, a stearylated amino acid~
In addition to the product of the invention being biocompatible, inexpensible and versatile, the matrix material has a long shelf life. Insulin-albumin microbeads, for example, may be stored at 4C for many months prior to implantation without loss of effectiveness.
The invention is illustrated further by the following Examples:
. ' . ,i i3 Exarnple 1 This Example illustrates the preparation of insulln-containing microbeads.
40 mg of beef insulin crystals (23.3 U/mg) were suspended in 0~8 ml of sodium phosphate buffer (1 mM, pH 7.5) containing sodium dodecyl sulfate (1%).
160 mg of bovine serum albumin (BSA~ of molecular weight of 67,000 Daltons was dissolved in the suspension which was maintained at 4C. Cross-linking was initiated by the addition of 0.2 ml of glutaraldehyde solution (2.5~ v/v) to provide a final glutaraldehyde concentration of 3.12% v/w of the albumin.
- After rapid mixing, the suspension was pipetted into 50 ml of a stirred solution of a corn oil and petroleum ether (1:4 by volume). The water-in-oil emulsion which formed was stirred at room temperature for fifteen minutes. The oil phase was decanted, the microbeads were washed three -times with petroleum ether and then dried overnight by weight of in a fume hood.
The dry microbeads contained 20% insulin and were stored dry at ~C.
Example 2 This Example illustrates the effect on blood sugar levels obtained by administration of the insulin microbeads formed by the procedure of Example 1.
(a) Implantation of Insulin Microbeads:
150 mg dry microbeads produced by the procedure of Example 1 were implanted subcutaneously in the flanks of chemically-induced diabetic rats, by means of a small incision in the skin. The blood insulin levels in the treated rats were monitored over a 21-day period and compared to those for untreated rats. The results are reproduced in the following Table I:
Table I
~ . ...
Days 0 3 7 10 14 17 21 Blood insulin 5 levels (~U/ml) ~treated diabetic rats (N=8) 14 51 62 75 63 38 21 -control diabetic rats (N=4) 11 6 9 10 6 3 9 10 As may be seen ~rom the results of Table I, after implantation of the microbeads, the insulin levels gradually increased to reach a maximum at 10 days post-implantation, after which there was a gradual decrease. The blood insulin level remained -elevated for up to 3 weeks after implantatlon, demonstrating the longevity of effectiveness of the product of the invention. There was no significant increase in blood-insulin levels in the con-trol animals.
The blood`glucose levels of the same diabetic rats with insulin microbead implants were monitored over the same 21-day period and again compared with -the non-treated rats. The results are reproduced in the following Table II:
Table II
Days 0 3 7 10 14 17 21 Blood sugar levels (mg%) -treated diabetic 30 rats (N=8) 370 95 91 84 105 305 380 -control diabe-tic rats (N=4) 380 390 387 392 400 404 406 As may be seen from the results of the above Table II, after implantation of the microbeads, the blood glucose levels fell from 370 mg per cent to 95 mg per cent and remained stable for 14 days. By day 21, all the animals were hyperglycemic. The control animals did not display any decrease in their high blood glucose levels.
i3 Body weight changes were also rnonitored during the test period and in all cases, the treated diabetic rats yained in weight while the control rats did not, as may be seen from the following Table III:
Table III
Days 0 3 7 10 14 Body weight (g) ~ -treated diabetic rats lu (N=8) 185 200 210 220 230 -control diabetic rats (N=4) 190 185 180 180 175 (b) Injection of Insulln Microbeads 40 mg of insulin microbeads were mixed with 2 ml of a glycerol/saline solution containing 75% of glycerol by weight and injected subcutaneously into diabetic rats with a 16~gauge needle. The results obtained were similar to those observed for implanted microbeads.
Example 3 This Example illustrates the effect of the concentration of glutaraldehyde used to cross-link albumin.
The procedure of Example 1 was repeated using varying concentrations of glutaraldehyde from 0.2 to 1.0~ v/v and, for the microbeads produced in each experiment, the effective period over which blood glucose levels were decreased was determined. In each case, 150 mg of insulin microbeads were subcutaneously implanted and the results reproduced in the following Table IV are a mean of three tests.
Table IV
~ Glut- 1.25 1.87 2.5 3.12 3.75 4.37 5.0 5.62 6.25 araldehyde v/w albumin No. of 11 13 13 14 0 0 0 0 0 days Blood Glucose levels lowered i3 As may be seen frorn the results of Table IV, at glu-taraldehyde concen-trations of 3.75~ v/w and above, the insulin microbeads are ineffective in producing a decrease in blood sugar levels, whereas sustained blood sugar control is achieved when the cross-linking is efCected usiny lower concentrations.
In summary of this disclosure, the present invention provides a novel long-acting implantable insulin composition which does not suffer from the drawbacks of prior art procedures. Modifications are possible within the scope of the invention.
Claims (9)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS
FOLLOWS:
1. A biodegradable insulin-containing composition suitable for administration to a living body for the control of blood sugar levels therein, comprising a matrix of partially cross-linked physically-native albumin and insulin wherein the extent of said partial cross-linking is such as to permit insulin to be released from the matrix by diffusion and/or erosion when positioned in the body.
2. The composition of claim 1 wherein said partial cross-linking is achieved by the use of glutaraldehyde in a concentration of less than 3.75%
v/w of the albumin.
v/w of the albumin.
3. The composition of claim 2 wherein the concentration of glutaraldehyde is about 1.25 to about 3.12% v/w of the albumin.
4. The composition of claim 1 in the form of injectable microbeads.
5. The composition of claim 1 wherein said insulin comprises about 5 to about 40% w/w of the composition.
6. A method of formation of an insulin-containing biodegradable composition, which comprises:
forming an aqueous suspension of native albumin, insulin crystals and glutaraldehyde in a concentration of less than 3.75% v/w of the albumin, adding said aqueous suspension to an oil phase under shear to form a water-in-oil emulsion and to cross-link the albumin to form microbeads of a matrix of partially cross-linked albumin and insulin which permit insulin to be released therefrom by diffusion and/or erosion when positioned in the body, and recovering the microbeads from the oil phase.
forming an aqueous suspension of native albumin, insulin crystals and glutaraldehyde in a concentration of less than 3.75% v/w of the albumin, adding said aqueous suspension to an oil phase under shear to form a water-in-oil emulsion and to cross-link the albumin to form microbeads of a matrix of partially cross-linked albumin and insulin which permit insulin to be released therefrom by diffusion and/or erosion when positioned in the body, and recovering the microbeads from the oil phase.
7. The method of claim 6 effected at a temperature less than about 20°C.
8. The method of claim 6 wherein the aqueous suspension has a pH of about 5.5 to about 8.5.
9. The method of claim 6 wherein the amount of insulin used provides about 5 to about 40% w/w of the composition.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000429960A CA1196863A (en) | 1983-06-08 | 1983-06-08 | Slow release injectable insulin composition |
| US06/505,840 US4492684A (en) | 1983-06-08 | 1983-06-20 | Slow release injectable insulin composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000429960A CA1196863A (en) | 1983-06-08 | 1983-06-08 | Slow release injectable insulin composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1196863A true CA1196863A (en) | 1985-11-19 |
Family
ID=4125435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000429960A Expired CA1196863A (en) | 1983-06-08 | 1983-06-08 | Slow release injectable insulin composition |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US4492684A (en) |
| CA (1) | CA1196863A (en) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL78826A (en) * | 1986-05-19 | 1991-05-12 | Yissum Res Dev Co | Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom |
| USRE35862E (en) * | 1986-08-18 | 1998-07-28 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
| DE3863027D1 (en) * | 1987-08-14 | 1991-07-04 | Akzo Nv | PREPARATION FOR PREVENTING OR FIGHTING COMPLICATIONS WITH DIABETES. |
| US4983402A (en) * | 1989-02-24 | 1991-01-08 | Clinical Technologies Associates, Inc. | Orally administerable ANF |
| US4976968A (en) * | 1989-02-24 | 1990-12-11 | Clinical Technologies Associates, Inc. | Anhydrous delivery systems for pharmacological agents |
| US5443841A (en) * | 1992-06-15 | 1995-08-22 | Emisphere Technologies, Inc. | Proteinoid microspheres and methods for preparation and use thereof |
| US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
| US5578323A (en) * | 1992-06-15 | 1996-11-26 | Emisphere Technologies, Inc. | Proteinoid carriers and methods for preparation and use thereof |
| US5447728A (en) * | 1992-06-15 | 1995-09-05 | Emisphere Technologies, Inc. | Desferrioxamine oral delivery system |
| WO1994023767A1 (en) * | 1993-04-22 | 1994-10-27 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5541155A (en) * | 1994-04-22 | 1996-07-30 | Emisphere Technologies, Inc. | Acids and acid salts and their use in delivery systems |
| US5714167A (en) * | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| US6099856A (en) * | 1992-06-15 | 2000-08-08 | Emisphere Technologies, Inc. | Active agent transport systems |
| US5693338A (en) * | 1994-09-29 | 1997-12-02 | Emisphere Technologies, Inc. | Diketopiperazine-based delivery systems |
| US6221367B1 (en) | 1992-06-15 | 2001-04-24 | Emisphere Technologies, Inc. | Active agent transport systems |
| SE9101381D0 (en) * | 1991-05-07 | 1991-05-07 | Tomas Moks | PEPTIDE HORMONE SOLUTION |
| FR2686899B1 (en) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| US5792451A (en) * | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5811127A (en) * | 1992-06-15 | 1998-09-22 | Emisphere Technologies, Inc. | Desferrioxamine oral delivery system |
| US5385606A (en) * | 1992-07-06 | 1995-01-31 | Kowanko; Nicholas | Adhesive composition and method |
| US5401516A (en) * | 1992-12-21 | 1995-03-28 | Emisphere Technologies, Inc. | Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof |
| US5643957A (en) * | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5958457A (en) * | 1993-04-22 | 1999-09-28 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
| US6461643B2 (en) * | 1993-04-22 | 2002-10-08 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5709861A (en) * | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
| US5965121A (en) * | 1995-03-31 | 1999-10-12 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5650386A (en) * | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| US6001347A (en) | 1995-03-31 | 1999-12-14 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5866536A (en) * | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6090958A (en) * | 1995-03-31 | 2000-07-18 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5989539A (en) * | 1995-03-31 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| CN1151836C (en) * | 1995-03-31 | 2004-06-02 | 艾米斯菲尔技术有限公司 | Compound and compositions for delivering active agents |
| US5820881A (en) * | 1995-04-28 | 1998-10-13 | Emisphere Technologies, Inc. | Microspheres of diamide-dicarboxylic acids |
| US5667806A (en) * | 1995-06-07 | 1997-09-16 | Emisphere Technologies, Inc. | Spray drying method and apparatus |
| US5824345A (en) * | 1995-06-07 | 1998-10-20 | Emisphere Technologies, Inc. | Fragrances and flavorants |
| US5750147A (en) * | 1995-06-07 | 1998-05-12 | Emisphere Technologies, Inc. | Method of solubilizing and encapsulating itraconazole |
| US6051258A (en) * | 1995-06-07 | 2000-04-18 | Emisphere Technologies, Inc. | Proteinoid emulsions and methods for preparation and use thereof |
| DE19681560T1 (en) * | 1995-09-11 | 1998-08-20 | Emisphere Tech Inc | Process for the preparation of omega-aminoalkanoic acid derivatives from cycloalkanones |
| US6231888B1 (en) | 1996-01-18 | 2001-05-15 | Perio Products Ltd. | Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps |
| AU2595697A (en) * | 1996-03-29 | 1997-10-22 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| JP2000512671A (en) | 1996-06-14 | 2000-09-26 | エミスフェアー テクノロジーズ インク | Microencapsulated fragrance and preparation method |
| US6358504B1 (en) * | 1997-02-07 | 2002-03-19 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5876710A (en) * | 1997-02-07 | 1999-03-02 | Emisphere Technologies Inc. | Compounds and compositions for delivering active agents |
| US6060513A (en) * | 1997-02-07 | 2000-05-09 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5990166A (en) * | 1997-02-07 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5804688A (en) * | 1997-02-07 | 1998-09-08 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5939381A (en) * | 1997-02-07 | 1999-08-17 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5879681A (en) * | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
| US6313088B1 (en) | 1997-02-07 | 2001-11-06 | Emisphere Technologies, Inc. | 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents |
| US5863944A (en) * | 1997-04-30 | 1999-01-26 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5962710A (en) * | 1997-05-09 | 1999-10-05 | Emisphere Technologies, Inc. | Method of preparing salicyloylamino acids |
| US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
| AU770316B2 (en) * | 1999-05-18 | 2004-02-19 | Cryolife, Inc. | Self-supporting, shaped, three-dimensional biopolymeric materials and methods |
| US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
| EP1274720A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | Albumin fusion proteins |
| US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2002097038A2 (en) * | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
| EP1463752A4 (en) * | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | Albumin fusion proteins |
| EP2277888A3 (en) * | 2001-12-21 | 2011-04-27 | Human Genome Sciences, Inc. | Fusion proteins of albumin and erythropoietin |
| US10098981B2 (en) | 2002-08-06 | 2018-10-16 | Baxter International Inc. | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
| US9101536B2 (en) * | 2002-08-06 | 2015-08-11 | Matrix Medical Llc | Biocompatible phase invertable proteinaceous compositions and methods for making and using the same |
| US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| NZ541365A (en) * | 2002-12-27 | 2009-09-25 | Diobex Inc | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2526957C (en) * | 2003-07-25 | 2011-07-12 | Conjuchem Inc. | Long lasting insulin derivatives and methods thereof |
| DE602005009658D1 (en) * | 2004-01-28 | 2008-10-23 | Csir Pretoria | STABILIZATION OF ENZYMES |
| US7553810B2 (en) | 2004-06-16 | 2009-06-30 | Pneumrx, Inc. | Lung volume reduction using glue composition |
| US7678767B2 (en) * | 2004-06-16 | 2010-03-16 | Pneumrx, Inc. | Glue compositions for lung volume reduction |
| WO2008036763A2 (en) * | 2006-09-20 | 2008-03-27 | Pneumrx, Inc. | Tissue adhesive compositions and methods thereof |
| CN102665676B (en) | 2009-11-02 | 2015-04-01 | 诺沃-诺迪斯克有限公司 | Pharmaceutical solution of non-covalently bound albumin and acylated insulin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1050353B (en) * | 1966-01-06 | 1981-03-10 | Ceskoslovenska Akademie Ved | SUPPORTS FOR BIOLOGICALLY ACTIVE SUBSTANCES |
| US3937668A (en) * | 1970-07-15 | 1976-02-10 | Ilse Zolle | Method for incorporating substances into protein microspheres |
| US3993071A (en) * | 1971-09-09 | 1976-11-23 | Alza Corporation | Bioerodible ocular device |
| US4349530A (en) * | 1980-12-11 | 1982-09-14 | The Ohio State University | Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal |
-
1983
- 1983-06-08 CA CA000429960A patent/CA1196863A/en not_active Expired
- 1983-06-20 US US06/505,840 patent/US4492684A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US4492684A (en) | 1985-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1196863A (en) | Slow release injectable insulin composition | |
| US5658593A (en) | Injectable compositions containing collagen microcapsules | |
| EP0263490B1 (en) | Sustained-release particulate preparation and process for preparing the same | |
| US5807581A (en) | Collagen-based injectable drug delivery system and its use | |
| CA1196862A (en) | Microencapsulation of living tissue and cells | |
| US4806355A (en) | Microencapsulation of living tissue and cells | |
| CA1217135A (en) | Collagen-thrombin compositions | |
| US4689293A (en) | Microencapsulation of living tissue and cells | |
| CA1196864A (en) | Controlled release of injectable and implantable insulin compositions | |
| DE69635940T2 (en) | Hydrogel matrix for cell tissue storage | |
| CA1257199A (en) | Preparation containing bioactive macromolecular substance for multi-months release in vivo | |
| JPS58121958A (en) | Collagen transplanting substance and method for reinforcing soft tissue | |
| EP0213908A2 (en) | Transplantable artificial tissue and process | |
| JPH08507713A (en) | Compositions and methods for tissue augmentation | |
| DD266272A5 (en) | METHOD FOR STABILIZING AN ANIMAL ORGANIC FARMING HORMONE | |
| JPH01265970A (en) | Collagen water solution or water dispersion solution including hyaluronic acid | |
| DE69725317T2 (en) | IMPLANTABLE AGAROSE COLLAGEN BALLS CONTAINING CELLS THAT MAKE A DIFFUSIONABLE BIOLOGICAL PRODUCT AND THEIR USE | |
| NZ224715A (en) | Mixed crystals of insulin and insulin derivatives, pharmaceutical compositions and methods of preparation | |
| Goosen et al. | Long-acting insulin: slow release of insulin from a biodegradable matrix implanted in diabetic rats | |
| DE60313982T2 (en) | DIMERS OF THROMBEPEPTIDE DERIVATIVES | |
| CN113713180A (en) | Cross-linked human albumin dermal filler and preparation method thereof | |
| CA2127885A1 (en) | Injectable compositions containing collagen microcapsules | |
| CA2662799A1 (en) | Method for producing insulin in the form of an oral preparation | |
| JPH06510035A (en) | Method of manufacturing biocompatible capsules containing cells | |
| US6605594B2 (en) | Aqueous glycerol formulations of somatotropin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry |